Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study

What Was Tested

Researchers studied Glatiramer Acetate in the context of multiple sclerosis in this randomized controlled trial publication.

These patients were drawn from 943 subjects who participated in the PROMiSe trial.

MRSI data were acquired by all the centers using the same pulse sequence, and spectral analysis was performed at a single site using a customized analysis software package.

Who Took Part

According to the abstract, 943 subjects were involved.

In these MRSI studies, patients were followed over a period of 3 years.

How the Study Was Run

In design terms this was a randomized, placebo-controlled and multicenter study.

Because people in this Glatiramer Acetate study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some subjects received a placebo instead of Glatiramer Acetate, giving a reference point.

Running at several centres spread the Glatiramer Acetate study over different clinics and patient groups.

The timeline in the abstract includes 3 years.

What Was Measured

Topics PubMed links to this paper include Aspartic Acid, Brain, Choline, Creatine, Glatiramer Acetate, Immunosuppressive Agents and Longitudinal Studies.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and multicenter study of Glatiramer Acetate in 943 subjects in people with multiple sclerosis over 3 years.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2008 (Multiple sclerosis (Houndmills, Basingstoke, England)), a journal based in England.

More context: the Glatiramer Acetate compound page, Multiple sclerosis research.